Rebiopsy Enhances Survival with Afatinib vs. Osimertinib in EGFR Exon 19 Deletion Non-Small Cell Lung Cancer: A Multicenter Study in Taiwan.
Saved in:
| Title: | Rebiopsy Enhances Survival with Afatinib vs. Osimertinib in EGFR Exon 19 Deletion Non-Small Cell Lung Cancer: A Multicenter Study in Taiwan. |
|---|---|
| Authors: | Kuo JS; Department of Internal Medicine, National Taiwan University Hospital Yunlin Branch, Yunlin County, Douliu City 640, Taiwan., Chang CY; Division of Chest Medicine, Department of Internal Medicine, Far Eastern Memorial Hospital, New Taipei City 220, Taiwan.; Department of Nursing, Cardinal Tien Junior College of Healthcare and Management, New Taipei City 231, Taiwan., Chang SC; Division of Chest Medicine, Department of Internal Medicine, National Yang-Ming Chiao Tung University Hospital, Yilan County, Yilan City 260, Taiwan., Wei YF; Department of Internal Medicine, E-Da Cancer Hospital, I-Shou University, Kaohsiung City 824, Taiwan.; School of Medicine for International Students, College of Medicine, I-Shou University, Kaohsiung City 824, Taiwan., Chen CY; Department of Internal Medicine, National Taiwan University Hospital Yunlin Branch, Yunlin County, Douliu City 640, Taiwan.; Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, College of Medicine, National Taiwan University, Taipei City 100, Taiwan. |
| Source: | Current oncology (Toronto, Ont.) [Curr Oncol] 2025 Jan 10; Vol. 32 (1). Date of Electronic Publication: 2025 Jan 10. |
| Publication Type: | Journal Article; Multicenter Study |
| Journal Info: | Publisher: MDPI Country of Publication: Switzerland NLM ID: 9502503 Publication Model: Electronic Cited Medium: Internet ISSN: 1718-7729 (Electronic) Linking ISSN: 11980052 NLM ISO Abbreviation: Curr Oncol Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
Be the first to leave a comment!
